PGIM Jennison Health Sciences Z
- PHSZX
- Price as of: Jul 23, 2021
-
$63.58
N/A N/A
- Primary Theme
- Health Care Sector Equity
- Fund Company
- Prudential
- Share Class
PHSZX - Snapshot
Vitals
- YTD Return 10.4%
- 3 Yr Annualized Return 17.0%
- 5 Yr Annualized Return 19.4%
- Net Assets $2.44 B
- Holdings in Top 10 38.6%
52 WEEK LOW AND HIGH
Expenses
OPERATING RELATED FEES
- Expense Ratio 0.85%
SALES FEES
- Front Load N/A
- Deferred Load N/A
BROKERAGE FEES
- Turnover 45.00%
TRADING FEES
- Max Redemption Fee N/A
Min Investment
- Standard (Taxable) $0
- IRA N/A
Fund Classification
-
Primary Theme
Health Care Sector Equity
- Fund Type Open End Mutual Fund
- Investment Style Health
PHSZX - Profile
Distributions
- YTD Total Return 10.4%
- 3 Yr Annualized Total Return 17.0%
- 5 Yr Annualized Total Return 19.4%
- Capital Gain Distribution Frequency Annually
- Net Income Ratio -0.29%
- Dividend Yield 0.0%
- Dividend Distribution Frequency Annually
Fund Details
-
Legal NamePGIM Jennison Health Sciences Fund
-
Fund Family NamePGIM Funds (Prudential)
-
Inception DateJun 30, 1999
-
Shares OutstandingN/A
-
Share ClassInst
-
CurrencyUSD
-
Domiciled CountryUnited States
-
ManagerDavid Chan
Fund Description
The fund seeks investments whose prices will increase over time. It normally invests at least 80% of its investable assets in equity and equity-related securities of companies within the health sciences sector, such as pharmaceutical companies, biotechnology companies, medical device manufacturers, healthcare service providers and health maintenance organizations (HMOs) and other companies that derive at least 50% of their assets, revenues or profits from operations in the healthcare sector. The fund is non-diversified.
PHSZX - Performance
Return Ranking - Trailing
| Period | PHSZX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | 10.4% | -80.9% | 31.0% | 37.56% |
| 1 Yr | 38.4% | -28.3% | 121.6% | 9.84% |
| 3 Yr | 17.0%* | 6.8% | 50.0% | 36.49% |
| 5 Yr | 19.4%* | 5.0% | 42.5% | 12.77% |
| 10 Yr | 18.5%* | 9.3% | 19.7% | 8.13% |
* Annualized
Return Ranking - Calendar
| Period | PHSZX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2020 | 17.7% | -13.6% | 178.2% | 32.56% |
| 2019 | 15.2% | 3.8% | 63.8% | 80.00% |
| 2018 | -13.5% | -49.7% | 21.5% | 81.02% |
| 2017 | 25.8% | -59.8% | 54.4% | 20.74% |
| 2016 | -17.2% | -36.6% | 11.6% | 64.06% |
Total Return Ranking - Trailing
| Period | PHSZX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | 10.4% | -80.9% | 31.0% | 37.56% |
| 1 Yr | 38.4% | -30.3% | 121.6% | 8.33% |
| 3 Yr | 17.0%* | -14.1% | 50.0% | 30.51% |
| 5 Yr | 19.4%* | -3.7% | 42.5% | 10.59% |
| 10 Yr | 18.5%* | 9.3% | 19.7% | 7.58% |
* Annualized
Total Return Ranking - Calendar
| Period | PHSZX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2020 | 17.7% | -13.6% | 178.2% | 32.56% |
| 2019 | 15.2% | 3.8% | 63.8% | 80.00% |
| 2018 | -13.5% | -25.3% | 22.2% | 82.48% |
| 2017 | 25.8% | -10.8% | 54.4% | 22.22% |
| 2016 | -17.2% | -36.6% | 11.6% | 73.44% |
NAV & Total Return History
PHSZX - Holdings
Concentration Analysis
| PHSZX | Category Low | Category High | PHSZX % Rank | |
|---|---|---|---|---|
| Net Assets | 2.44 B | 2.67 M | 51.7 B | 24.43% |
| Number of Holdings | 85 | 11 | 506 | 43.53% |
| Net Assets in Top 10 | 941 M | 2.19 K | 19.3 B | 18.97% |
| Weighting of Top 10 | 38.62% | 7.2% | 94.7% | 56.03% |
Top 10 Holdings
- UnitedHealth Group Inc 6.87%
- Humana Inc 6.05%
- Immunomedics Inc 4.95%
- Eli Lilly and Co 4.93%
- Natera Inc 3.43%
- Danaher Corp 3.34%
- Intellia Therapeutics Inc 3.34%
- Apellis Pharmaceuticals Inc 3.21%
- Becton, Dickinson and Co 3.10%
- DexCom Inc 3.02%
Asset Allocation
| Weighting | Return Low | Return High | PHSZX % Rank | |
|---|---|---|---|---|
| Stocks | 98.91% | 82.66% | 104.58% | 63.79% |
| Other | 1.09% | -26.05% | 9.11% | 9.91% |
| Preferred Stocks | 0.03% | 0.00% | 5.23% | 8.62% |
| Convertible Bonds | 0.00% | 0.00% | 0.03% | 43.10% |
| Bonds | 0.00% | 0.00% | 17.12% | 46.12% |
| Cash | -0.03% | -0.13% | 17.34% | 97.41% |
Stock Sector Breakdown
| Weighting | Return Low | Return High | PHSZX % Rank | |
|---|---|---|---|---|
| Healthcare | 98.34% | 62.01% | 100.00% | 79.31% |
| Basic Materials | 1.30% | 0.00% | 8.53% | 8.19% |
| Financial Services | 0.37% | 0.00% | 2.61% | 14.22% |
| Utilities | 0.00% | 0.00% | 0.83% | 43.10% |
| Technology | 0.00% | 0.00% | 19.82% | 49.57% |
| Real Estate | 0.00% | 0.00% | 6.19% | 46.55% |
| Industrials | 0.00% | 0.00% | 6.41% | 47.84% |
| Energy | 0.00% | 0.00% | 0.93% | 43.10% |
| Communication Services | 0.00% | 0.00% | 8.10% | 45.26% |
| Consumer Defense | 0.00% | 0.00% | 29.47% | 47.84% |
| Consumer Cyclical | 0.00% | 0.00% | 18.45% | 48.71% |
Stock Geographic Breakdown
| Weighting | Return Low | Return High | PHSZX % Rank | |
|---|---|---|---|---|
| US | 82.35% | 56.42% | 104.03% | 61.21% |
| Non US | 16.56% | 0.00% | 40.85% | 33.62% |
PHSZX - Expenses
Operational Fees
| PHSZX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Expense Ratio | 0.85% | 0.08% | 2.91% | 40.53% |
| Management Fee | 0.73% | 0.00% | 1.25% | 60.80% |
| 12b-1 Fee | N/A | 0.00% | 1.00% | N/A |
| Administrative Fee | N/A | 0.03% | 0.25% | N/A |
Sales Fees
| PHSZX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Front Load | N/A | 0.00% | 5.75% | N/A |
| Deferred Load | N/A | 1.00% | 5.00% | N/A |
Trading Fees
| PHSZX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Max Redemption Fee | N/A | 1.00% | 2.00% | N/A |
Related Fees
Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.
| PHSZX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Turnover | 45.00% | 3.00% | 256.00% | 50.62% |
PHSZX - Distributions
Dividend Yield Analysis
| PHSZX | Category Low | Category High | PHSZX % Rank | |
|---|---|---|---|---|
| Dividend Yield | 0.00% | 0.00% | 0.70% | 48.28% |
Dividend Distribution Analysis
| PHSZX | Category Low | Category High | Category Mod | |
|---|---|---|---|---|
| Dividend Distribution Frequency | Annually | Annually | Monthly | Annually |
Net Income Ratio Analysis
| PHSZX | Category Low | Category High | PHSZX % Rank | |
|---|---|---|---|---|
| Net Income Ratio | -0.29% | -2.54% | 1.92% | 64.33% |
Capital Gain Distribution Analysis
| PHSZX | Category Low | Category High | Capital Mode | |
|---|---|---|---|---|
| Capital Gain Distribution Frequency | Annually | Annually | Annually | Annually |
PHSZX - Fund Manager Analysis
Managers
David Chan
Start Date
Tenure
Tenure Rank
Jun 30, 1999
22.02
22.0%
David Chan, CFA, is a Managing Director and a Health Sciences Equity Portfolio Manager and Research Analyst of Jennison. Mr. Chan joined Jennison Associates in May 1992. He was previously with the Boston Consulting Group, where he was a team leader and consultant on projects in a wide variety of industries, but with a special focus in the health care area. Mr. Chan has also worked in various positions in the film and television industry. He received a BA in biochemistry from Harvard University and an MBA from Columbia University.
Debra Netschert
Start Date
Tenure
Tenure Rank
Jan 28, 2015
6.42
6.4%
Debra Netschert is a Managing Director and a Health Sciences Equity Portfolio Manager and Research Analyst of Jennison. Ms. Netschert joined Jennison Associates in January 2008. Prior to Jennison, Ms. Netschert worked at Magnetar Capital where she was a senior analyst responsible for health care coverage with an emphasis on biotechnology and pharmaceutical industries. Prior to her experience at Magnetar Capital, Ms. Netschert worked at Amaranth Advisors as a biotechnology analyst. From 2002 to 2004, she was vice president and senior analyst for biotechnology at Lazard Capital Markets. Ms. Netschert began her research career as an associate biotechnology analyst at UBS in 2000. She received her BS and MS from Boston University.
Daniel Matviyenko
Start Date
Tenure
Tenure Rank
Dec 15, 2020
0.54
0.5%
Daniel Matviyenko is a Managing Director and health sciences equity portfolio manager. He joined Jennison in December 2020. Before joining Jennison, Mr. Matviyenko was founder, chief investment officer, and portfolio manager at Malleus Capital. Prior to founding Malleus, he was a portfolio manager, managing director, and partner at Tudor Investment. Prior to that, Mr. Matviyenko was a portfolio manager and an executive director at UBS O'Connor. Mr. Matviyenko holds a BS in finance from the University of Connecticut.
Tenure Analysis
| Category Low | Category High | Category Average | Category Mode |
|---|---|---|---|
| 0.02 | 23.81 | 6.75 | 1.21 |